Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Medicinal research reviews (Print)

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/med.21345PMID 25847027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

  2023cited by this paper
• Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.

  2015cited by this paper
• Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent.

  2014cited by this paper
• Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

  2014cited by this paper
• Trastuzumab-Conjugated Liposome-Coated Fluorescent Magnetic Nanoparticles to Target Breast Cancer

  2014cited by this paper
• Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

  2014cited by this paper
• Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

  2014cited by this paper
• Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

  2014cited by this paper
• Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds.

  2014cited by this paper
• Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.

  2014cited by this paper
• Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

  2014cited by this paper
• Eradication of Growth of HER2-Positive Ovarian Cancer With Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate in Mouse Xenograft Model

  2014cited by this paper
• Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

  2014cited by this paper
• Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

  2014cited by this paper
• Trastuzumab emtansine: mechanisms of action and drug resistance

  2014cited by this paper
• Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.

  2013cited by this paper
• Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

  2013cited by this paper
• Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.

  2013cited by this paper
• AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

  2013cited by this paper
• Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

  2013cited by this paper
• Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.

  2013cited by this paper
• Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

  2012cited by this paper
• Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

  2012cited by this paper
• The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

  2012cited by this paper
• Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.

  2012cited by this paper
• Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.

  2012cited by this paper
• Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

  2011cited by this paper
• MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

  2011cited by this paper
• Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

  2011cited by this paper
• Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles.

  2011cited by this paper
• Polyhedral Oligomeric Silsesquioxanes‐Containing Conjugated Polymer Loaded PLGA Nanoparticles with Trastuzumab (Herceptin) Functionalization for HER2‐Positive Cancer Cell Detection

  2011cited by this paper
• Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

  2011cited by this paper
• Mechanisms and management of doxorubicin cardiotoxicity

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011influential reference
• Abstract 618: Role of multidrug resistance transporters in the biological response to trastuzumab-cytotoxic drug conjugates

  2010cited by this paper
• Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma: Comparison With FISH and Assessment of Interobserver Reproducibility

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.

  2010cited by this paper
• Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.

  2010cited by this paper
• Trastuzumab in gastric cancer.

  2010cited by this paper
• The role of HER2 in cancer therapy and targeted drug delivery.

  2010cited by this paper
• Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.

  2010cited by this paper
• Water-soluble conjugated polymers as the platform for protein sensors

  2010cited by this paper
• Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

  2010cited by this paper
• Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells

  2009cited by this paper
• Resistance to Trastuzumab in Breast Cancer

  2009cited by this paper
• Optimizing the cationic conjugated polymer-sensitized fluorescent signal of dye labeled oligonucleotide for biosensor applications.

  2009cited by this paper
• Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.

  2009cited by this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cited by this paper
• HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

  2009cited by this paper
• Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

  2009cited by this paper
• Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.

  2009cited by this paper
• Targeted Herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI

  2009cited by this paper
• Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines

  2009cited by this paper
• Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

  2009cited by this paper
• Trastuzumab for gastric cancer

  2009cited by this paper
• Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.

  2008cited by this paper
• Optical detection of DNA and proteins with cationic polythiophenes.

  2008cited by this paper
• Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.

  2008cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Rapid generation of protein aerosols and nanoparticles via SAW atomisation

  2008cited by this paper
• HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb

  2008cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Cell killing by antibody-drug conjugates.

  2007cited by this paper
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  2007cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

  2006cited by this paper
• Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006cited by this paper
• Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

  2006cited by this paper
• Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.

  2006cited by this paper
• Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

  2006cited by this paper
• Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Gene medicines: the end of the beginning?

  2005cited by this paper
• Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry

  2005cited by this paper
• Adjuvant trastuzumab for HER2-positive breast cancer.

  2005cited by this paper
• Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.

  2004cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.

  2004cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.

  2004cited by this paper
• The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

  2003cited by this paper
• Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum

  2002cited by this paper
• Trastuzumab‐associated cardiotoxicity

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Mechanism of action of trastuzumab and scientific update.

  2001cited by this paper

• Omega-3 polyunsaturated fatty acids ameliorate high-fat-diet-induced structural and functional impairments of testicular tissue via ER stress inhibition

  2025cites this paper
• Effect of formulation composition on trastuzumab stability.

  2025cites this paper
• Development of phenylboronic acid functionalized poly (lactic-co-glycolic acid) nanoparticles for novel co-delivery of chemo-herbal combination towards lung cancer: an in silico and in vitro proof of concept.

  2025cites this paper
• Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes.

  2024cites this paper
• Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses

  2024cites this paper
• Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma

  2023influential citation
• Review on Metal-Based Theranostic Nanoparticles for Cancer Therapy and Imaging

  2023cites this paper
• Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis

  2023cites this paper
• Trastuzumab conjugated PEG – Fe3O4@Au nanoparticle as an MRI biocompatible nano-contrast agent

  2022cites this paper
• Potential of Iron Oxide Nanoparticles as Drug Delivery Vehicle

  2021cites this paper
• The role of nanoparticles in the treatment of gastric cancer

  2021cites this paper
• Surface engineered dendrimers as novel option for enhanced pharmaceutical and biomedical potential

  2021cites this paper
• Nanotechnology Applications in Gastric Cancer

  2020cites this paper
• Theranostics Approaches to Gastric and Colon Cancer

  2020cites this paper
• Trastuzumab Conjugated Porphyrin-Superparamagnetic Iron Oxide Nanoparticle: A Potential PTT-MRI bimodal Agent for Herceptin Positive Breast Cancer.

  2020cites this paper
• In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina

  2019cites this paper
• A Review of Theranostics Applications and Toxicities of Carbon Nanomaterials.

  2019cites this paper
• Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment.

  2019cites this paper
• Nanomedicine in Gastric Cancer

  2019cites this paper
• Monoclonal Antibody-Conjugated Dendritic Nanostructures for siRNA Delivery.

  2019cites this paper
• HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor.

  2019cites this paper
• Targeting Strategies for SuperParamagnetic Iron Oxide Nanoparticles in Cancer Therapy.

  2019cites this paper
• Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo

  2018cites this paper
• 6.02 – Cancer Immunotherapy

  2017cites this paper
• Targeted delivery of anticancer drugs: new trends in lipid nanocarriers

  2017cites this paper
• investigating the functionalization of colloidal nanoparticles with small molecules of biological interest

  2017cites this paper
• Use of Nanomedicine in the Diagnosis of Gastric Cancer

  2017cites this paper
• Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery.

  2017cites this paper
• Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer

  2017cites this paper
• The application of nanoparticles in diagnosis and theranostics of gastric cancer.

  2017cites this paper
• Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

  2017cites this paper
• Focused ultrasound induced hyperthermia accelerates and increases the uptake of anti-HER-2 antibodies in a xenograft model.

  2016cites this paper
• Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer

  2016cites this paper
• Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.

  2016cites this paper
• Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment

  2016cites this paper
• HER2/ERBB2 immunoreactivity in human retinoblastoma

  2016cites this paper